Blog
RSS FeedPosted by Michael Wonder on 14 Sep 2022
Independent review of paracetamol overdose
14 September 2022 - The TGA has published an independent expert report examining the incidence of serious injury and death ...
Posted by Michael Wonder on 13 Sep 2022
ICER releases draft evidence report on gene therapies for haemophilia A and B
13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...
Posted by Michael Wonder on 13 Sep 2022
ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis
13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...
Posted by Michael Wonder on 09 Sep 2022
PBAC Public Summary Documents (first time rejections and deferrals) - May 2022 meeting
9 September 2022 - The Public Summary Documents (first time rejections and deferrals) from the May 2022 PBAC meeting are now ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 01 Sep 2022
ACE publishes another tranche of technology guidances (August 2022)
31 August 2022 - Six technology guidance documents were published yesterday. ...
Posted by Michael Wonder on 31 Aug 2022
ICER publishes evidence report on treatments for obesity management
31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...
Posted by Michael Wonder on 26 Aug 2022
PBAC Public Summary Documents – May 2022 meeting
26 August 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2022 PBAC ...
Posted by Michael Wonder on 12 Aug 2022
2022-2023 cost recovery implementation statement
12 August 2022 - The 2022-23 PBS and NIP cost recovery implementation statement is now available. ...
Posted by Michael Wonder on 19 Jul 2022
ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
Posted by Michael Wonder on 15 Jul 2022
PBAC Public Summary Documents (first time rejections and deferrals) – March 2022 meeting
15 July 2022 - The Public Summary Documents (first time rejections and deferrals) from the March 2022 PBAC meeting are now ...
Posted by Michael Wonder on 13 Jul 2022
ICER releases draft evidence report on treatments for obesity management
13 July 2022 - Registration now open for 26 July “Early Insights” webinar. ...
Posted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 01 Jul 2022
Public Summary Documents – March 2022 PBAC meeting
1 July 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2022 PBAC ...
Posted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...